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Atrial ﬁbrillation (AF) is the most common cardiac rhythm
disorder (1) and can result in negative cardiovascular out-
comes such as stroke and mortality, especially in patients
with cardiovascular morbidities (2,3). AF also contributes
substantially to the cost of medical care (4), of which
stroke-related care is a large component. Clinical trials
have fundamentally supported the concepts used by cli-
nicians in the management of AF including rate and
rhythm control, use of interventional procedures such as
ablation, and anticoagulation for the prevention of stroke
and thromboembolism (5,6). Despite these guidelines,See page 2141there is no clear consensus in real-world practice on how
AF patients should be managed with respect to the
available data, with the exception that patients with AF
and risk factors for stroke should be treated with an
anticoagulant in the absence of a contraindication to such
an agent. Despite the relative lack of controversy sur-
rounding AF and anticoagulation in appropriate patients,
anticoagulants are underutilized by cardiovascular spe-
cialists and even more so by primary care providers. The
recent American College of Cardiology PINNACLE
(Practice Innovation and Clinical Excellence) registry
data showed a rate of only 57% for anticoagulant use in
AF patients (7). The reasons for such underutilization are*Editorials published in the Journal of the American College of Cardiology reﬂect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Arrhythmia Service and Electrophysiology Fellowship Program, Alpert
Medical School of Brown University, and Cardiovascular Institute, Rhode Island
Miriam and Newport Hospitals, Providence, Rhode Island. Dr. Kim is a consultant
with Boehringer Ingelheim, BMS/Pﬁzer, and Daichi-Sankyo; and has ﬁnancial
relationships with Boehringer Ingelheim, Bristol-Myers Squibb/Pﬁzer, and
Daichi-Sankyo.many and have not improved signiﬁcantly even with the
availability of warfarin alternatives over the past few
years. These “novel oral anticoagulants” or “target-speciﬁc
oral anticoagulants” have shown efﬁcacy that is either
improved or comparable to that of warfarin (8,9) but have
not markedly increased the rate of overall anticoagulation
use in appropriate AF patients.
Much of the focus on anticoagulation in AF has been in
data demonstrating the efﬁcacy in reducing stroke and
thromboembolism. However, it is the other side of the
coin, speciﬁcally, the concern over bleeding that has limited
the adoption of anticoagulants in AF patients. In this issue
of the Journal, Hylek et al. (10) present data from the
ARISTOTLE (Apixaban for Reduction in Stroke and
Other Thromboembolic Events in Atrial Fibrillation) trial
regarding the on-treatment safety population (n ¼ 18,140
patients). In comparison to well-managed warfarin anti-
coagulation, apixaban therapy was associated with dem-
onstrated beneﬁts in adverse bleeding outcomes including
a reduction in both intracranial and extracranial major
hemorrhage (hazard ratio 0.69; p < 0.001). More im-
portantly, these reduced adverse bleeding outcomes
translated to a 50% decrease in total mortality in the next
30 days (p < 0.001). In addition, major extracranial
hemorrhages on apixaban therapy resulted in fewer
hospital stays, medical or surgical interventions, blood
transfusions, and changes in anticoagulant therapy than
on warfarin. The reduction in incidence of intracranial
hemorrhage has been shown for the 3 currently approved
novel anticoagulants (apixaban, dabigatran, rivaroxaban).
These ﬁndings highlight the need for a differential
approach to anticoagulant therapy in AF. Hylek et al. (10)
identiﬁed multiple independent risk factors such as older
age, prior hemorrhage, prior stroke or transient ischemic
attack (TIA), diabetes, lower hematocrit level, and renal
dysfunction that were predictive of a ﬁrst major hemorrhage.
Female sex was also found in the multivariable model to
have a lower risk of major hemorrhage. Not surprisingly, the
use of aspirin and non-steroidal anti-inﬂammatory drugs
increased the risk of major bleeding. Other than helping to
elucidate predictors of major hemorrhage and to charac-
terize major bleeding events, the most important aspect
of this paper was the presentation of the concept of the
“challenge of shared risk factors for stroke and hemorrhage
among individuals with AF.” Older age, previous stroke,
and renal dysfunction were the most prominent factors
for both stroke and major bleeding. These data clearly show
that a singular approach toward anticoagulation for AF
is not appropriate and that balancing the risk of ischemic
stroke and thromboembolism with the risk of major
bleeding is the preferred dual treatment target. This is most
important in those patients with not only a high risk of
ischemic stroke but also major bleeding. The identiﬁcation
of the at-risk population is the ﬁrst step in addressing the
net clinical beneﬁt of targeted stroke reduction and reduced
bleeding outcomes.
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2149Anticoagulation for AF is at a crossroads in therapy, with
a movement toward novel anticoagulants as they provide
either superior or noninferior ischemic stroke prevention and
overall a comparable or reduced bleeding proﬁle in com-
parison with that of warfarin. These new data for more
speciﬁc, reduced bleeding outcomes with 1 of the novel
anticoagulants, apixaban, adds more data to the movement
away from warfarin for nonvalvular AF. In this investigation,
warfarin use was associated with more major hemorrhage
and more hospital stays for bleeding, transfusions, pro-
cedural interventions for bleeding, and changes in antico-
agulant therapy which may have been related to the worse
outcomes. Furthermore, as the authors note, the presence of
agents that reverse the effect of warfarin by lowering the
international normalized ratio does not necessarily have clear
positive clinical outcomes. The novel anticoagulants offer
advantages that argue for a lower threshold for anti-
coagulation (11). The message appears to be negative in the
recent past regarding warfarin for AF, especially in light of
the data for novel anticoagulants.
From a management standpoint, AF is best viewed as
a “disease” with a variety of presentations from lone AF
to one of many comorbid conditions, often in the very
elderly. This heterogeneity makes the anticoagulation
dilemma particularly difﬁcult in terms of a recommenda-
tion to administer anticoagulants or not and which speciﬁc
anticoagulant to use. Warfarin therapy reduces stroke by
64% and is associated with a decrease in all-cause mor-
tality in AF (3). There has been a recent decline in stroke
mortality driven by a reduced incidence of stroke and
lower rates of death when stroke occurs (12), perhaps in
part due to warfarin and improved stroke management.
An analysis of warfarin use in Medicare beneﬁciaries from
2000 to 2010 was associated with reductions in stroke,
hospital stays, and mortality across the Medicare popu-
lation (13). Furthermore, from a value-based analysis of
quality adjusted life years, warfarin may have economic
value in the cost-constrained health system which exists
today (14).
Despite the increasingly more positive data regarding
novel anticoagulants, warfarin should not be abandoned nor
overly ostracized for its negative points. Rather, it should be
viewed as 1 of multiple choices in the tool box of antico-
agulants that may be used for the shared risk assessment in
determining the choice of anticoagulant therapy or no
therapy in low risk or contraindicated patients. Under-
scoring this clinical dilemma of anticoagulant choice is the
poor performance of clinicians in prescribing anticoagulants
for AF in general. This fact may be the more important
public health and quality of care issue. Other than more
comprehensive risk assessment for net clinical beneﬁt
with equal consideration of both ischemic stroke and
bleeding potential, efforts should be directed to improve
anticoagulation rates in appropriate AF patients. The
implementation of publically reportable performance mea-
sures and cardiovascular outcomes, readily availableclinician and health system feedback, and ﬁnancial risk
would likely improve anticoagulation rates beyond medical
education. The potential availability of functional antidotes
for the novel anticoagulants or major cost reductions such
as generic options in the future will also drive anti-
coagulation use upward.
A dilemma can be viewed as a problem offering 2 pos-
sibilities, neither of which is practically acceptable, or
rhetorically, that you must accept 1 of the choices with each
leading to some undesired conclusion. Yes, anticoagulation
in AF is a clinical dilemma, but substantial amounts of data
support the therapy. Clinicians do not see the strokes pre-
vented, but they do see occurrences of major bleeding. Data
from this investigation provide more support for a more
complete view beyond efﬁcacy of ischemic stroke reduction
by including more concrete data for major bleeding, with a
comparative perspective to well-managed warfarin therapy.
Much more data are needed in this area to ﬁll gaps in
knowledge through continued research, especially in sub-
groups of patients in different clinical scenarios and with
multiple comorbidities. Evaluation of racial and sex dispar-
ities would also be beneﬁcial. Where data are lacking, it is
hoped that the various specialty medical societies can provide
recommendations to clinicians, using the best available evi-
dence to date. Most of what happens in health care is
provider-dependent and through the use of cardiovascular
outcomes as the guide to navigate through the dilemma,
both individual- and population-level beneﬁts for our AF
patients can be achieved.Reprint requests and correspondence to: Dr. Michael H. Kim,
Cardiovascular Institute of Rhode Island and Miriam Hospitals,
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